LENSAR (NASDAQ:LNSR) Announces Quarterly Earnings Results

LENSAR (NASDAQ:LNSR) announced its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.28), FiscalAI reports. The firm had revenue of $14.13 million for the quarter, compared to analyst estimates of $14.30 million. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%.

Here are the key takeaways from LENSAR’s conference call:

• Recurring revenue rose 17% to $12.6 million, procedure revenue increased 17%, and procedure volume grew 12% year over year. Recurring revenue made up 89% of total revenue, helping offset a 1% decline in total revenue as system sales fell against a strong prior-year comparison.
• LENSAR placed 10 ALLY systems, bringing its installed base to approximately 225, while market share edged up to 24.5%. The company said new robotic docking features are expected around the end of Q1 2027, potentially supporting further adoption.
• Gross margin improved to 58% from 42%, operating loss narrowed to about $1.4 million, and adjusted EBITDA turned positive at $1.7 million. GAAP net loss widened to $4.7 million, largely due to a non-cash warrant-liability expense.
• Management described overseas commercial activity as still recovering after distributor disruption, seasonal holidays, and reimbursement changes, and expects a gradual ramp into 2027. Executives also noted that U.S. cataract procedure volumes have recently been slightly softer.
• Cash and investments were $12.6 million at quarter-end, supplemented by a new $10 million revolving credit line. Management anticipates $1 million–$2 million of cash burn for the rest of 2026 and said it expects to move closer to break-even at some point in 2027.

LENSAR Stock Down 4.6%

Shares of NASDAQ:LNSR traded down $0.21 during trading on Wednesday, hitting $4.41. 42,475 shares of the company traded hands, compared to its average volume of 90,468. The stock has a market capitalization of $54.15 million, a price-to-earnings ratio of -13.35 and a beta of 1.03. The business’s fifty day moving average is $6.65 and its 200-day moving average is $7.29. LENSAR has a one year low of $4.41 and a one year high of $12.94.

Analysts Set New Price Targets

Several research firms recently issued reports on LNSR. Weiss Ratings raised LENSAR from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 22nd. Wall Street Zen downgraded shares of LENSAR from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Loop Capital set a $11.00 target price on shares of LENSAR in a research note on Monday, September 28th. Lake Street Capital reissued a “buy” rating and set a $13.00 target price on shares of LENSAR in a report on Thursday, August 13th. Finally, BTIG Research dropped their target price on shares of LENSAR from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, LENSAR has an average rating of “Hold” and a consensus target price of $11.00.

LENSAR News Summary

Here’s some of the latest news about LNSR:

• Positive Sentiment: Recurring revenue rose 17% year over year to $12.6 million, or about 89% of quarterly revenue. LENSAR placed 10 ALLY robotic cataract laser systems during the quarter and reported a 12-system backlog; its total installed base reached 450 systems, with the ALLY base up 22% year over year. LENSAR third-quarter results and business update
• Positive Sentiment: The company anticipates introducing robotic docking features by the end of the first quarter of 2027, which could support its product offering and future growth. Seeking Alpha article on planned robotic docking features
• Negative Sentiment: Third-quarter EPS was a loss of $0.38, substantially worse than the $0.10 loss analysts expected. Revenue of $14.13 million also came in slightly below the $14.30 million consensus, while the reported net loss widened to about $4 million—likely the main near-term pressure on shares. RTT News report on LENSAR’s third-quarter loss

LENSAR Company Profile

LENSAR, Inc. is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation. Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.